ライフサイエンスコーパス: cell transplant

1 3%) to lenalidomide; 39 (59%) had prior stem cell transplant.

2 re not planned for immediate autologous stem-cell transplant.

3 reatment that included an HIV-resistant stem cell transplant.

4 um-based chemotherapy before autologous stem cell transplant.

5 secutive patients undergoing allogeneic stem cell transplant.

6 n those who had undergone hematopoietic stem cell transplant.

7 tic progenitor cells in preparation for stem cell transplant.

8 ical malignancies and the recipients of stem-cell transplant.

9 h-dose melphalan therapy and autologous stem cell transplant.

10 development of allogeneic hematopoietic stem cell transplant.

11 engineered T cells 2 d after autologous stem cell transplant.

12 ion after unrelated-donor hematopoietic stem cell transplant.

13 in lymphoma received chemotherapy and a stem cell transplant.

14 e treatment or autologous or allogeneic stem-cell transplant.

15 to identify an etiology, 6 weeks after stem cell transplant.

16 free without a consolidative allogeneic stem cell transplant.

17 ib treatment and high-dose melphalan in stem cell transplant.

18 ortality after allogeneic hematopoietic stem cell transplant.

19 ortality after allogeneic hematopoietic stem cell transplant.

20 tion in first remission with autologous stem cell transplant.

21 s proceeding to a subsequent allogeneic stem-cell transplant.

22 ion is a significant complication after stem cell transplant.

23 at cancer diagnosis and haematopoietic stem-cell transplant.

24 e resection or allogeneic hematopoietic stem cell transplant.

25 from recipients of allogeneic hematopoietic cell transplant.

26 and mortality after allogeneic hematopoietic cell transplant.

27 those who had undergone a hematopoietic stem cell transplant.

28 erapy in combination with hematopoietic stem cell transplant.

29 nt for primary disease is hematopoietic stem cell transplant.

30 s host disease in matched or mismatched stem cell transplants.

31 educe the rate of relapse in allogeneic stem cell transplants.

32 omide), and 76% had received autologous stem-cell transplants.

33 :CLEC2D) interactions in human hematopoietic cell transplants.

34 on in recipients of allogeneic hematopoietic-cell transplants.

35 ressive therapies and/or solid organ or stem cell transplants.

36 human lymphoid tissue and hematopoietic stem cell transplants.

37 s, particularly those who have received stem cell transplants.

38 aftment rates, with similar numbers of CD34+ cells transplanted.

39 patients had relapsed after allogeneic stem-cell transplants, 13 (76%) had previously received thera

40 ncrystalline LCPT, of whom 11 underwent stem cell transplant, 16 received chemotherapy only, and nine

41 had undergone autologous hematopoietic stem-cell transplant 50 to 70 days earlier.

42 Autologous hematopoietic cell transplant (AHCT) for HIV-infected patients is larg

43 Allogeneic hematopoietic cell transplant (allo-HCT) can be curative for certain h

44 lity to distinguish allogeneic hematopoietic cell transplant (allo-HCT) recipients at risk for cytome

45 complication facing allogeneic hematopoietic cell transplant (allo-HCT) recipients, as a result of in

46 on a cohort of 237 allogeneic hematopoietic cell transplant (allo-HCT) recipients, that can predict

47 ty and mortality in allogeneic hematopoietic cell transplant (allo-HCT) recipients.

48 plant (autoHCT) and allogeneic hematopoietic cell transplant (alloHCT).

49 Most clinical allogeneic hemopoietic cell transplants (alloHCT) are now performed using reduc

50 arting treatment achieved hematopoietic stem cell transplant (alloHSCT) compared with 46% in the imat

51 In hematopoietic cell transplants, alloreactive T cells mediate the graft

52 do not appear to require an allogeneic stem cell transplant (alloSCT) if they achieve a good respons

53 lication among allogeneic hematopoietic stem cell transplant (alloSCT) recipients.

54 and poor-risk patients (PR) allogeneic stem cell transplant (AlloSCT).

55 Stem cell transplant ameliorated clinical symptoms in one pat

56 mobilized stem cells all accepted their stem cell transplant and became tolerant to the VCA.

57 c (Allo) and autologous (Auto) hematopoietic cell transplant and CD19-directed chimeric antigen recep

58 nts in need of allogeneic hematopoietic stem cell transplant and has recruited millions of volunteers

59 young males with cALD prior to hematopoietic cell transplant and its association with markers of cere

60 ed by high-dose therapy with autologous stem cell transplant and subsequent antidisialoganglioside an

61 , persons with autologous hematopoietic stem cell transplant and those without graft-versus-host dise

62 n additional 300 patients who underwent stem cell transplant and were enrolled on multicentre clinica

63 of the children received hematopoietic stem cell transplants and all showed poor graft function with

64 By overcoming the limitations of stem cell transplants and better understanding the mechanisms

65 Recent studies with single cell transplants and lineage tracing suggest that adult

66 biologic therapy such as hematopoietic stem cell transplants and mesenchymal cell infusions.

67 ibody is associated with early graft loss of cell transplants and reduced long-term survival of solid

68 consolidative hematopoietic allogeneic stem cell transplant, and 9 (9% of all enrolled patients) rem

69 mised diagnosis and history of hematopoietic cell transplant, and among survivors immunocompromised p

70 iver, bowel, pancreas, heart, lung, and stem-cell transplant, and blood transfusion.

71 lds of solid organ transplant, hematopoietic cell transplant, and organ donation.

72 mmunosuppressive drugs, 13 had received stem cell transplants, and 7 were infected with human immunod

73 ngenital immunodeficiency, and hematopoietic cell transplant are independently associated with an inc

74 ients of a solid organ or hematopoietic stem cell transplant are living longer with a better quality

75 The majority of allogeneic stem cell transplants are currently undertaken using G-CSF mo

76 an adequate blood supply for the survival of cell transplants are major hurdles that need to be overc

77 genetically corrected autologous airway stem cell transplant as a treatment for CF.

78 on emission tomography or hematopoietic stem cell transplant as independent prognostic factors for ou

79 e-ferumoxytol-positive macrophages into stem cell transplants, as visualized with IVM and histopathol

80 with high-dose chemotherapy, autologous stem cell transplant (ASCT) and long-term immunomodulatory dr

81 ients initially treated with autologous stem cell transplant (ASCT) at Mayo Clinic.

82 RD) for 6 cycles followed by autologous stem cell transplant (ASCT) conditioned with IV busulfan + me

83 addition of 211At-CD38 to an autologous stem cell transplant (ASCT) conditioning regimen may improve

84 dose chemotherapy (HDC) with autologous stem-cell transplant (ASCT) may provide an alternative to add

85 Utilization of autologous stem cell transplant (ASCT) was similar across all periods, a

86 actory myeloma undergoing an autologous stem-cell transplant (ASCT).

87 g cytarabine, rituximab, and autologous stem-cell transplant (ASCT).

88 alvage chemotherapy (SC) and autologous stem cell transplant (ASCT).

89 halan with low-dose TBI after haplocord stem cell transplant assures good engraftment and leads to ac

90 eletal muscle after brown adipose progenitor cell transplant augments energy expenditure.

91 atients (FR) were to receive autologous stem cell transplant (AuSCT) and poor-risk patients (PR) allo

92 a (AML), as well as autologous hematopoietic cell transplant (autoHCT) and allogeneic hematopoietic c

93 The addition of an autologous stem cell transplant before cART withdrawal alters viral dyna

94 Unexpectedly, MGE cells transplanted before injury prevented the developme

95 mes of patients who underwent haplocord stem cell transplant between May 2013 and March 2015 and who

96 Hematopoietic cell transplant candidates and recipients with respirato

97 ent admissions with a non-hematopoietic stem cell transplant cohort and excluded solid-organ transpla

98 ortality was 32.9% in non-hematopoietic stem cell transplant cohort, which was similar to autologous

99 hen compared with the non-hematopoietic stem cell transplant cohort.

100 Among patients without hematopoietic cell transplant, congenital immunodeficiency (adjusted o

101 imaging of donor-matched and mismatched stem cell transplants demonstrated decreased signal intensity

102 esis that selective GABA agonists as well as cell transplant-derived GABA are antipruritic against ac

103 Allogeneic stem cell transplants differ from conventional tissue transpl

104 Allogeneic cells transplanted directly to the liver do not enjoy im

105 ority of patients in need of a hematopoietic-cell transplant do not have a matched related donor.

106 high-dose chemotherapy with autologous stem-cell transplant failure were included.

107 blative chemotherapy with hematopoietic stem-cell transplant followed by adjuvant retinoid differenti

108 icient SCID (ADA-SCID) is hematopoietic stem cell transplant from an HLA-matched sibling donor, altho

109 received a first myeloablative hematopoietic-cell transplant from an unrelated cord-blood donor (140

110 gh) CTLs) in 53/115 CMV IgG(+) patients stem cell transplanted from CMV IgG(+) donors.

111 itive recipients of allogeneic hematopoietic-cell transplants from matched related or unrelated donor

112 ents with crystalline LCPT treated with stem cell transplant had stable or improved kidney function,

113 undergoing haploidentical hematopoietic stem cell transplant (haplo-HSCT) without the risk for uncont

114 a formidable challenge to the hematopoietic cell transplant (HCT) and kidney transplant fields.

115 Hematopoietic cell transplant (HCT) and solid organ transplant (SOT) r

116 yndrome (BOS) after allogeneic hematopoietic cell transplant (HCT) conferred nearly universal mortali

117 man herpesvirus 6 (ciHHV-6) in hematopoietic cell transplant (HCT) donors or recipients confounds mol

118 ve chemotherapy and the use of hematopoietic cell transplant (HCT) for specific high-risk groups.

119 Only hematopoietic cell transplant (HCT) has been shown to halt neurologic

120 tory virus infections prior to hematopoietic cell transplant (HCT) is difficult.

121 us-host disease (cpGVHD) after hematopoietic cell transplant (HCT) manifests as progressive airway an

122 therapy (HDIT) with autologous hematopoietic cell transplant (HCT) may, in contrast, induce sustained

123 omosome (HY-Abs) develop after hematopoietic cell transplant (HCT) of male recipients with female don

124 lasia (MDS), and in allogeneic hematopoietic cell transplant (HCT) recipients (early, until day 40; l

125 ults of MVA in allogeneic hematopoietic stem cell transplant (HCT) recipients and Triplex in healthy

126 Hematopoietic cell transplant (HCT) recipients are frequently infected

127 lid organ transplant (SOT) and hematopoietic cell transplant (HCT) recipients are limited.

128 commend vaccinating allogeneic hematopoietic cell transplant (HCT) recipients at 3 months after trans

129 commend vaccinating allogeneic hematopoietic cell transplant (HCT) recipients at 3 months after trans

130 lid organ transplant (SOT) and hematopoietic cell transplant (HCT) recipients at a single center over

131 disseminated viral disease in hematopoietic cell transplant (HCT) recipients but does not lead to re

132 egalovirus (CMV) infections in hematopoietic cell transplant (HCT) recipients cause substantial morbi

133 integrated HHV-6 (iciHHV-6) in hematopoietic cell transplant (HCT) recipients is unclear.

134 e aimed to compare outcomes of hematopoietic cell transplant (HCT) recipients treated with oral or ae

135 including (i) whole blood from hematopoietic cell transplant (HCT) recipients with and without HHV-6B

136 th substantial morbidity among hematopoietic cell transplant (HCT) recipients, but the etiology is of

137 with significant mortality in hematopoietic cell transplant (HCT) recipients.

138 a surveillance method for hematopoietic stem cell transplant (HCT) recipients.

139 auses significant morbidity in hematopoietic cell transplant (HCT) recipients.

140 eatment trials are lacking for hematopoietic cell transplant (HCT) recipients.

141 e respiratory disease in adult hematopoietic cell transplant (HCT) recipients.

142 fe-threatening complication in hematopoietic cell transplant (HCT) recipients.

143 th hematologic malignancies or hematopoietic cell transplant (HCT) recipients.

144 ct of human bocavirus (BoV) in hematopoietic cell transplant (HCT) recipients.

145 apsed CLL following allogeneic hematopoietic cell transplant (HCT) who subsequently received ibrutini

146 and symptom burden during hematopoietic stem-cell transplant (HCT).

147 s of both solid-organ and hematopoietic stem cell transplant (HCT).

148 logic malignancy or undergoing hematopoietic cell transplant (HCT).

149 ies (HMs) and in recipients of hematopoietic cell transplant (HCT).

150 ty (NRM) after unrelated donor hematopoietic cell transplant (HCT).

151 reactivation early after hematopoietic stem cell transplant (HCT).

152 diagnosing pulmonary IMI after hematopoietic cell transplant (HCT).

153 ex vivo T-cell depleted (TCD) hematopoietic cell transplant (HCT).

154 cations in adult patients with hematopoietic cell transplants (HCT), cancer (hematologic and solid tu

155 cations in adult patients with hematopoietic cell transplants (HCT), cancer, human immunodeficiency v

156 atients who receive allogeneic hematopoietic cell transplants (HCTs), and the skin is the most common

157 after high-dose therapy and autologous stem-cell transplant (HDT/ASCT) for patients with relapsed or

158 ng survivors of pediatric hematopoietic stem cell transplant (HSCT) are understudied.

159 y and mortality following hematopoietic stem cell transplant (HSCT) because of various hematologic pr

160 Allogeneic hematopoietic stem cell transplant (HSCT) can be curative, but suitable don

161 Therapeutic hematopoietic stem cell transplant (HSCT) during chronic infection generate

162 potential benefit after haematopoietic stem cell transplant (HSCT) for patients with refractory CD.

163 missions for induction or hematopoietic stem-cell transplant (HSCT) from 2006 to 2014 was selected.

164 Autologous hematopoietic stem cell transplant (HSCT) has been effective in treating ot

165 The field of hematopoietic stem cell transplant (HSCT) has made ground-breaking progress

166 Hematopoietic stem cell transplant (HSCT) is the only cure for sickle cell

167 Autologous and allogeneic hematopoietic stem cell transplant (HSCT) patients are susceptible to pulmo

168 g reactivation of HCMV in hematopoietic stem cell transplant (HSCT) patients soluble Gal-9 is upregul

169 the pediatric allogeneic hematopoietic stem cell transplant (HSCT) population is unknown.

170 V-seronegative allogeneic hematopoietic stem cell transplant (HSCT) recipient is generally accepted.

171 irus (CMV) viral loads in hematopoietic stem cell transplant (HSCT) recipients are typically monitore

172 he risk of skin cancer in hematopoietic stem-cell transplant (HSCT) recipients has not been extensive

173 is a high-risk feature in hematopoietic stem cell transplant (HSCT) recipients with transplant-associ

174 ed in >/=9% of allogeneic hematopoietic stem cell transplant (HSCT) recipients, in whom it can cause

175 fectious complications in hematopoietic stem cell transplant (HSCT) recipients.

176 nts, including allogeneic hematopoietic stem cell transplant (HSCT) recipients.

177 tality in solid organ and hematopoietic stem cell transplant (HSCT) recipients.

178 ize cerebral disease is a hematopoietic stem cell transplant (HSCT).

179 ortality after allogeneic hematopoietic stem cell transplant (HSCT).

180 frequent complications of hematopoietic stem cell transplant (HSCT).

181 interest in the field of hematopoietic stem cell transplant (HSCT).

182 organ transplant (SOT) or hematopoietic stem cell transplant (HSCT).

183 d or unrelated allogeneic hematopoietic stem cell transplant (HSCT).

184 en complicating allograft hematopoietic stem cell transplant (HSCT).

185 ections often occur after hematopoietic stem cell transplant (HSCT); vaccination is important for pre

186 ration site analysis in a hematopoietic stem cell-transplanted humanized mouse model.

187 cured following a delta32/delta32 CCR5 stem cell transplant in 2007 revealed no antibodies against p

188 age chemotherapy followed by autologous stem cell transplant in chemosensitive disease.

189 Allogeneic stem cell transplant in second remission is the only curative

190 suggests that the rejection of similar stem cell transplants in humans will be dependent upon the pr

191 owever, the outcomes of fetal tissue-derived cell transplants in individuals with Parkinson disease h

192 ons could reduce the number of hematopoietic cell transplants in patients with AML by 20-25% while ma

193 n contrast, Sharpin(cpdm) mammary epithelial cells transplanted in vivo into wild-type stroma, fully

194 thin 100 days after allogeneic hematopoietic cell transplant increases risk of pulmonary complication

195 he Lancet of embryonic-stem-cell-derived RPE cell transplants indicate no serious adverse outcomes an

196 clophosphamide (C)-based haploidentical stem-cell transplants indicates that this drug may re-orchest

197 Skeletal muscle stem (satellite) cells transplanted into host mouse muscles contribute to

198 Normal H2-K1(high) cells transplanted into injured lungs differentiate into

199 Unexpectedly, cells transplanted into naive spinal cord prevented the

200 into old recipients; conversely, young beta-cells transplanted into old mice decrease their replicat

201 ave increased replication rate compared with cells transplanted into old recipients; conversely, youn

202 Furthermore, human CD34(+) cells transplanted into ossicle-bearing mice engrafted a

203 w that for encapsulated rat pancreatic islet cells transplanted into streptozotocin-treated diabetic

204 Enteric neural cells transplanted into the bowel give rise to multiple

205 Likewise, Ctcf-null MGE cells transplanted into the cortex of wild-type hosts ge

206 In addition, we demonstrate that old beta-cells transplanted into young recipients have increased

207 e their replication rate compared with young cells transplanted into young recipients.

208 HD) occurring after allogeneic hematopoietic cell transplant is an allo-reactive T cell and inflammat

209 The role of allogeneic hematopoietic stem cell transplant is less clear but may be useful in selec

210 In myelofibrosis, stem cell transplant is the current treatment of choice for g

211 Among patients with prior hematopoietic cell transplant, liquid malignancy (adjusted odds ratio,

212 ia-like" regimen followed by allogeneic stem-cell transplant may be advisable; addition of a tyrosine

213 s of hematopoiesis and develop hematopoietic cell transplant methodology.

214 We used a Panc02 pancreatic tumor cell transplant model in diet-induced obese (DIO) C57BL/

215 own postnatal mice-plus syngeneic fibroblast cell-transplant models-we demonstrate that the regenerat

216 y Hodgkin lymphoma following autologous stem cell transplant (N = 102) after a median observation per

217 66; HR = 0.66; P = .001) and autologous stem cell transplant (n = 273; HR = 0.55; P = .004) were inde

218 2.39-6.07) and autologous hematopoietic stem cell transplant (odds ratio, 1.28; 95% CI, 1.06-1.53) re

219 l mortality in allogeneic hematopoietic stem cell transplant (odds ratio, 3.81; 95% CI, 2.39-6.07) an

220 m surgical biopsies that include mesenchymal cells transplanted on biodegradable scaffolds.

221 We found that primary ALL cells transplanted onto nonobese diabetic/severe combine

222 sing between high-dose chemotherapy and stem cell transplant or bortezomib-based chemotherapy.

223 a who previously received an autologous stem cell transplant or two previous multiagent chemotherapy

224 Mice receiving 5-LO-deficient cell transplant or zileuton treatment had prolonged surv

225 conditioning regimen for hematopoietic stem cell transplant (P = .002), and the cumulative dose of c

226 ctive review of 738 allogeneic hematopoietic cell transplant patients enrolled from 2005 to 2011.

227 y of pediatric cancer and hematopoietic stem cell transplant patients requiring continuous renal repl

228 infused 12 haploidentical hematopoietic stem cell transplant patients with increasing numbers of allo

229 s of pediatric cancer and hematopoietic stem cell transplant patients, 68 of 70 evaluable patients wh

230 n a longitudinal study of hematopoietic stem cell transplant patients, bone marrow- and liver-enriche

231 nts of solid organ transplantation, and stem cell transplant patients, emphasizing the parallels betw

232 ovirus (CMV) infection in hematopoietic stem cell transplant patients.

233 ng and in solid-organ and hematopoietic stem cell transplant patients.

234 dds of mortality than non-hematopoietic stem cell transplant patients.

235 n lymphocyte reconstitution in hematopoietic cell transplant patients.

236 ificantly higher than non-hematopoietic stem cell transplant patients.

237 n in pediatric cancer and hematopoietic stem cell transplant patients.

238 ng patients who received blood-building stem cell transplants, patients with chronic granulomatous di

239 Among patients with hematopoietic stem cell transplant, persons with autologous hematopoietic s

240 idomide/pomalidomide, double autologous stem cell transplant plus bortezomib, or combination of immun

241 a promising biomaterial for delivery of stem cell transplant populations, with no adverse effects on

242 The use of tacrolimus in our islet-cell transplant protocol caused an initial 20% reduction

243 ection was diagnosed in a hematopoietic stem cell transplant recipient during conditioning regimen.

244 lovirus encephalitis in a hematopoietic stem cell transplant recipient.

245 was similar to autologous hematopoietic stem cell transplant recipients (30.1%) and those who did not

246 us complications in allogeneic hematopoietic cell transplant recipients (alloHCT).

247 ant recipients (n = 197), 0% to 5.8% in stem-cell transplant recipients (n = 103), and 11.2 to 15.2%

248 Autologous hematopoietic stem cell transplant recipients and those who do not develop

249 Hematopoietic stem cell transplant recipients are more likely to be immunoc

250 Hematopoietic stem cell transplant recipients are more likely to develop se

251 a cluster of fatal toxoplasmosis among stem cell transplant recipients at 2 hospitals, surveillance

252 It is widely used in hematopoietic cell transplant recipients but is infrequently utilized

253 isk for MS in pediatric solid organ and stem cell transplant recipients by comparing them with matche

254 unit knockout mice, we demonstrate that stem cell transplant recipients lacking the ability to genera

255 host disease treatment in hematopoietic stem cell transplant recipients often results in prolonged or

256 t cytomegalovirus infection in hematopoietic cell transplant recipients provided initial data on the

257 fects of GvHD itself, all serve to make stem cell transplant recipients vulnerable to disease from en

258 uency of severe sepsis in hematopoietic stem cell transplant recipients was five times higher when co

259 ion therapy or allogeneic hematopoietic stem cell transplant recipients were randomized (1:1 ratio) t

260 in subsequent admissions, hematopoietic stem cell transplant recipients with graft-versus-host diseas

261 We compared outcomes of hematopoietic stem cell transplant recipients with severe sepsis during eng

262 A total of 21,898 hematopoietic stem cell transplant recipients with severe sepsis were ident

263 patients (renal transplant recipients, stem cell transplant recipients, and congenitally infected ch

264 on adoptive transfer into hematopoietic stem cell transplant recipients, CAR-expressing lymphoid prog

265 been successfully used in hematopoietic stem cell transplant recipients, its extension to the SOT set

266 taneous malignant neoplasms in hematopoietic cell transplant recipients, this population should be ed

267 included: infant ALL, relapsed ALL, and stem cell transplant recipients.

268 or survival in allogeneic hematopoietic stem cell transplant recipients.

269 ral control in allogeneic hematopoietic stem cell transplant recipients.

270 sus-host disease in allogeneic hematopoietic cell transplant recipients.

271 dose-range-finding prophylaxis study in stem-cell transplant recipients.

272 ality of severe sepsis in hematopoietic stem cell transplant recipients.

273 tality in solid organ and hematopoietic stem cell transplant recipients.

274 ication codes to identify hematopoietic stem cell transplant recipients.

275 asive aspergillosis among hematopoietic stem cell transplant recipients.

276 gical malignancies and in hematopoietic stem cell transplant recipients.

277 lder adults and autologous haemopoietic stem cell transplant recipients.

278 omplication in solid organ and hematopoietic cell transplant recipients.

279 (cGVHD) after allogeneic hematopoietic stem cell transplant reflects a complex immune response resul

280 JMML relies on allogeneic hematopoietic stem cell transplant, relapse is the most frequent cause of t

281 CMV pneumonia in recipients of hematopoietic cell transplant remains a significant challenge.

282 f stem cells from the BM and autologous stem cell transplant rescued RIL in mice.

283 linical factors, induction therapy, and stem cell transplant (SCT) on the outcomes of 311 patients wi

284 R patients, 16 received a consolidative stem cell transplant (SCT) with median PFS not reached.

285 tients who relapse following autologous stem cell transplant (SCT), multiple treatment options are av

286 < 0.0001) and not undergoing allogeneic stem cell transplant (SCT, p = 0.0005) predicted poor overall

287 g risk in patients receiving allogeneic stem cell transplants (SCTs) or chemotherapy but not in those

288 d by their new position following progenitor cell transplant, such that a ventral olfactory receptor

289 , and may be applicable to many encapsulated cell transplant systems.

290 Allogeneic stem cell transplant, the only treatment modality shown to ha

291 ronal and retinal development and ultimately cell-transplant therapy.

292 herapy regimens and allogeneic hematopoietic cell transplant to achieve the best long-term outcomes.

293 nts in 3 medical centers using hematopoietic cell transplants to establish mixed or complete chimeris

294 ) outbreak in a hematology-oncology and stem cell transplant unit.

295 Allogeneic hematopoietic stem cell transplant was offered to selected patients in firs

296 Salvage high-dose chemotherapy plus a stem-cell transplant was required in six (6%) patients in the

297 ine-containing regimen, or haemopoietic stem-cell transplant were also excluded.

298 recipients of allogeneic hematopoietic stem cell transplants who underwent GBCA-enhanced MR imaging

299 detection of innate immune responses to stem cell transplants with magnetic resonance (MR) imaging.

300 detection of innate immune responses to stem cell transplants with MR imaging.

301 recipients of allogeneic hematopoietic stem cell transplant, with their infections caused by five Le